ScoreComparison
Why is Human Metabolome Technologies, Inc. ?
1
The company has declared positive results in Jun'2026 after 4 consecutive negative quarters
- NET SALES(Q) At JPY 314.75 MM has Grown at 66.86%
- NET PROFIT(Q) At JPY 34.64 MM has Grown at 167.1%
- RAW MATERIAL COST(Y) Fallen by -36.45% (YoY)
2
With ROE of 5.10%, it has a very expensive valuation with a 2.05 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -16.80%, its profits have fallen by -67.3%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -16.80% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Human Metabolome Technologies, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Human Metabolome Technologies, Inc. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Human Metabolome Technologies, Inc.
-17.59%
-0.21
26.59%
Japan Nikkei 225
43.58%
1.48
29.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.27%
EBIT Growth (5y)
33.10%
EBIT to Interest (avg)
90.48
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0.68
Tax Ratio
9.19%
Dividend Payout Ratio
34.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
42.24%
ROE (avg)
11.07%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
2.05
EV to EBIT
23.98
EV to EBITDA
11.57
EV to Capital Employed
4.72
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.68%
ROE (Latest)
5.10%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET SALES(Q)
At JPY 314.75 MM has Grown at 66.86%
NET PROFIT(Q)
At JPY 34.64 MM has Grown at 167.1%
RAW MATERIAL COST(Y)
Fallen by -36.45% (YoY
DIVIDEND PER SHARE(HY)
Highest at JPY 6.63
PRE-TAX PROFIT(Q)
At JPY -2.8 MM has Grown at 97.24%
-2What is not working for the Company
ROCE(HY)
Lowest at 10.72%
Here's what is working for Human Metabolome Technologies, Inc.
Net Sales
At JPY 314.75 MM has Grown at 66.86%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (JPY MM)
Net Profit
At JPY 34.64 MM has Grown at 167.1%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Pre-Tax Profit
At JPY -2.8 MM has Grown at 97.24%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Dividend per share
Highest at JPY 6.63
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Raw Material Cost
Fallen by -36.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
